SCHEMBL7560583

SCHEMBL7560583

O=C(NN=Cc1ccc[nH]1)c1[nH]c2ccccc2c1-c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.60
NPC1 O15118 1/20 0.60
GAA P10253 2/20 0.58
MAPT P10636 9/20 0.57
LMNA P02545 7/20 0.57
ALDH1A1 P00352 6/20 0.57
HPGD P15428 4/20 0.57
PAX8 Q06710 2/20 0.57
KMT2A Q03164 8/20 0.53
MEN1 O00255 7/20 0.53
KDM4E B2RXH2 4/20 0.53
MAP2 P11137 1/20 0.52
RECQL P46063 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
POLB P06746 2/20 0.52
CRHBP P24387 1/20 0.52
CRHR2 Q13324 1/20 0.52
TP53 P04637 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.50
TUBB4A P04350 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7560582 1.00 RAB9A (0.60) RAB9ANPC1GAAMAPTLMNA
SCHEMBL7567200 0.84 MAPT (0.75) RAB9ANPC1GAAMAPTLMNA
SCHEMBL7567198 0.84 MAPT (0.75) RAB9ANPC1GAAMAPTLMNA
SCHEMBL7565124 0.84 PADI4 (0.55) RAB9AGAAMAPTLMNAALDH1A1
SCHEMBL7565116 0.84 PADI4 (0.55) RAB9AGAAMAPTLMNAALDH1A1
SCHEMBL7557568 0.81 MAPT (0.55) RAB9ANPC1GAAMAPTLMNA
SCHEMBL7557566 0.81 MAPT (0.55) RAB9ANPC1GAAMAPTLMNA
SCHEMBL7530988 0.81 ALDH1A1 (0.77) RAB9ANPC1GAAMAPTLMNA
SCHEMBL7560935 0.81 ALDH1A1 (0.77) RAB9ANPC1GAAMAPTLMNA
SCHEMBL7676056 0.80 MAPT (0.54) RAB9AGAAMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 RAB9A 3961/4885NPC1 3749/4885GAA 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.